Skip to Content
  • Easterbrook Post Updated

    I wanted to point out the update at the end of the “Cold Equations” post below, in case anyone’s interested. There’s been a lot of mail on this one, as you’d imagine – but so far, nothing defending Gregg Easterbrook’s analysis. If anyone out there is minded to do that, I’d like to hear it. Read More
  • Drug Prices

    More on Prices, High and Otherwise

    The key questions raised in the e-mail I quoted in the last post are: is it fair to fund drug research through high prices on drugs? And especially, is it fair to do so by raising prices on individual drugs, rather than across the board? My answer to the first question, as you’d guess, is… Read More
  • The Cold Equations

    Here’s a question for the folks at The New Republic: are you really sure that Gregg Easterbrook’s blog is a good idea? Just checking. He’s already stepped into so many steaming mudholes that I’m starting to think that he’s one of those born-to-be-edited types. (Or would that help?) I say this in response to today’… Read More
  • Drug Prices

    The Contact Sport of Cost Accounting

    I have just enough time to post an interesting e-mail, from Nick H. in the Netherlands, responding to the links I posted the other day about research costs. “I agree that accountants calculate costs in the way described, but accountants do a lot of accounting in ways which aren’t always quite fair to all stakeholders. Read More
  • Business and Markets

    I will do such things – What they are yet I know not. . .

    Igor Landau of Aventis must have been seen a performance of King Lear recently, to judge from his tactics to fend off Sanofi’s hostile takeover bid. Or since the following also has a “Do you feel lucky?” ring to it, maybe they’ve been watching old Clint Eastwood movies instead. Surely those have been dubbed into… Read More
  • Drug Prices

    Darn Those R&D Costs, Anyway

    I wanted to pass along a couple of recent articles that address drug pricing and research costs. It’s a subject that attracts nonsense like a cloud of gnats; every so often you have to shoo them off. Here’s a fine post from Alex Tabarrok at Marginal Revolution: In 2003, Joseph DiMasi, Ronald Hansen, and Henry… Read More
  • Cardiovascular Disease

    Sic Transit Gloria Mundi

    So Entremed is finally giving up on its celebrated peptide drug candidates, angiostatin and endostatin. I’m sorry to see what the company, and its employees have been through, but I’m even sorrier when I think about what cancer patients have been through during this story. Especially those of them who read that (in)famous New York… Read More
  • How Not to Do It

    Our Friend, the Carbon-Aluminum Bond

    “Twenty-five years of being a laboratory chemist, says Gregory Hlatky today, and this is the first time I’ve had an incident.” Hey, maybe he’s been doing the wrong kind of chemistry. Some kinds can almost guarantee you an incident every month or two! Actually, the kind of chemistry he does (organometallics) is already pretty… Read More
  • Chem/Bio Warfare

    Ricin Redux

    Now that the suspected ricin in the Senate (and White House?) has been confirmed, I thought I’d repost a version of something I wrote about a year ago on my previous site, Lagniappe. (This was written after British authorities had rounded up several suspects in London who had some ricin of their own.) So what… Read More
  • Patents and IP

    How to Be an Inventor

    While I’m talking about inventorship on patents, I should note that there’s a factor that doesn’t get the attention it deserves: luck. Well, not the public attention, anyway. But talk to any group of researchers about who gets on which patent, or whose lab produced the most active compounds in any given project, and the… Read More